Treatment Dose Increase Versus Co‐Medication in Allergic Rhinitis: Systematic Review With Dose–Response Network Meta‐Analysis
Allergy · 2026-11 · 81 (11) · 3797-3812
DOI: 10.1111/all.70372 ↗At a glance
Systematische Übersicht in Allergy, published online on 2026-05-01. Written by Bernardo Sousa-Pinto and 21 co-authors. Institution: MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences; Faculty of Medicine, University of Porto, Porto, Portugal. Major MEDLINE topics: Rhinitis, Allergic, Anti-Allergic Agents, Histamine Antagonists. 30 references. The full text is freely available (open access, CC BY 4.0). Funded by: ARIA (Allergic Rhinitis and its Impact on Asthma), Montpellier, France, Advanced Research and Invention Agency.
Abstract (original language)
Background
To achieve adequate symptom control, patients with allergic rhinitis (AR) often need to increase their medication dose or add other treatments (co‐medication). We aimed to perform a systematic review to compare the efficacy and safety of AR medications for increased dose versus co‐medication.
Methods
We searched four bibliographic databases and three trial databases for randomised controlled trials assessing the effect of intranasal and/or oral medications in patients of all ages with seasonal or perennial AR. We performed pairwise meta‐analysis based on direct evidence to compare (i) non‐standard versus standard treatment doses, and (ii) co‐medication strategies versus monotherapy using standard doses. Furthermore, we fitted dose–response network meta‐analysis (NMA) to obtain projected estimates for comparisons involving two times the standard dose of AR medications in monotherapy versus co‐medication with the standard dose of the same medications. We assessed the certainty of evidence using GRADE for NMA.
Results
We included 262 studies. Co‐medication schemes involving oral antihistamines (OAH) + intranasal corticosteroids (INCS) resulted in higher improvements of nasal symptoms and quality of life than doubling the dose of OAH. However, doubling the dose of intranasal medications led to better results than having intranasal medications + OAH. Doubling the dose of INCS was associated with higher efficacy than adding intranasal antihistamines (INAH). No relevant safety differences were found between treatment strategies.
Conclusions
Results favoured (i) doubling the dose of intranasal medications versus adding OAH, and (ii) adding INCS to OAH over doubling the dose of OAH. This study will inform the ARIA‐EAACI 2024–2025 guidelines.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences; Faculty of Medicine, University of Porto, Porto, Portugal.
- CINTESIS@RISE-Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal.
- Allergy Unit, Instituto and Hospital CUF, Porto, Portugal.
- Unit of Anatomy, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal.
- Clinical Epidemiology and Research Center (CERC), Humanitas University and Humanitas Research Hospital, Milan, Italy.
- Department of Health Research Methods, Evidence, and Impact & Department of Medicine, Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada.
ORCID profiles: Bernardo Sousa-Pinto, Rafael José Vieira, Ana Margarida Pereira, Antonio Bognanni, Mattia Giovannini, Ludger Klimek, Holger J Schünemann, Guido Schwarzer, Jean Bousquet
Funding
- ARIA (Allergic Rhinitis and its Impact on Asthma), Montpellier, France
- Advanced Research and Invention Agency
Cite
APA
Sousa-Pinto, B., Vieira, R. J., Gil-Mata, S., Pereira, A. M., Duarte, V. H., Bognanni, A., Marques-Cruz, M., Jemioło, P., Giovannini, M., di Bona, D., Agarwal, A., Dykewicz, M. S., Shamji, M. H., Torres, M. J., Zuberbier, T., Klimek, L., Chu, A. W. L., Schünemann, H. J., Schwarzer, G., …, & ARIA 2024–2025 systematic reviews group (2026). Treatment Dose Increase Versus Co‐Medication in Allergic Rhinitis: Systematic Review With Dose–Response Network Meta‐Analysis. Allergy, 81(11), 3797-3812. https://doi.org/10.1111/all.70372
Vancouver
Sousa-Pinto B, Vieira RJ, Gil-Mata S, Pereira AM, Duarte VH, Bognanni A, et al. Treatment Dose Increase Versus Co‐Medication in Allergic Rhinitis: Systematic Review With Dose–Response Network Meta‐Analysis. Allergy. 2026;81(11):3797-3812. doi:10.1111/all.70372
BibTeX
@article{SousaPinto2026,
author = {Sousa-Pinto, Bernardo and Vieira, Rafael José and Gil-Mata, Sara and Pereira, Ana Margarida and Duarte, Vítor Henrique and Bognanni, Antonio and Marques-Cruz, Manuel and Jemioło, Paweł and Giovannini, Mattia and di Bona, Danilo and Agarwal, Arnav and Dykewicz, Mark S and Shamji, Mohamed H and Torres, Maria Jose and Zuberbier, Torsten and Klimek, Ludger and Chu, Alexandro W L and Schünemann, Holger J and Schwarzer, Guido and Fonseca, João A and Bousquet, Jean and ARIA 2024–2025 systematic reviews group, ARIA 2024–2025 systematic reviews group},
title = {Treatment Dose Increase Versus Co‐Medication in Allergic Rhinitis: Systematic Review With Dose–Response Network Meta‐Analysis},
journal = {Allergy},
year = {2026},
volume = {81},
number = {11},
pages = {3797--3812},
doi = {10.1111/all.70372}
}
EUVIMED